These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35788363)

  • 21. Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis.
    Geusens P; Feldman R; Oates M; Thomas T; Makras P; Jakob F; Langdahl B; Wang Z; Rojeski M; Libanati C
    Bone; 2022 Jan; 154():116209. PubMed ID: 34547521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone Mass Gains After One Denosumab Injection Followed by Zoledronate.
    Everts-Graber J; Lehmann T
    J Clin Densitom; 2022; 25(3):293-298. PubMed ID: 35450795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple severe vertebral fractures during the 3-month period following a missed dose of denosumab in a postmenopausal woman with osteoporosis previously treated with alendronate
.
    Bandeira F; Torres G; Bandeira E; Duarte MB; Nóbrega AM; Bandeira L
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):163-166. PubMed ID: 30663978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Multiple vertebral fractures after denosumab discontinuation].
    Tjelum L; Eiken P
    Ugeskr Laeger; 2018 Nov; 180(45):. PubMed ID: 30404716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of denosumab on back pain-related disability and quality-of-life in patients with vertebral fragility fractures.
    Moretti A; de Sire A; Curci C; Toro G; Gimigliano F; Iolascon G
    Curr Med Res Opin; 2019 Jan; 35(1):151-155. PubMed ID: 30406685
    [No Abstract]   [Full Text] [Related]  

  • 26. When and how to stop denosumab therapy in a patient with osteoporosis.
    Goulden EL; Crowley RK
    Clin Endocrinol (Oxf); 2023 May; 98(5):649-653. PubMed ID: 35470448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Denosumab: A Review in Postmenopausal Osteoporosis.
    Deeks ED
    Drugs Aging; 2018 Feb; 35(2):163-173. PubMed ID: 29435849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for poor response to denosumab treatment in Japanese postmenopausal women with osteoporosis.
    Okawa T; Okawa M; Koike T
    J Bone Miner Metab; 2022 Nov; 40(6):960-967. PubMed ID: 35939236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis.
    Yang L; Kang N; Yang JC; Su QJ; Liu YZ; Guan L; Liu T; Meng XL; Wang Y; Hai Y
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2640-2668. PubMed ID: 30964193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.
    Miller PD; Wagman RB; Peacock M; Lewiecki EM; Bolognese MA; Weinstein RL; Ding B; San Martin J; McClung MR
    J Clin Endocrinol Metab; 2011 Feb; 96(2):394-402. PubMed ID: 21159841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.
    Ebina K; Etani Y; Tsuboi H; Nagayama Y; Kashii M; Miyama A; Kunugiza Y; Hirao M; Okamura G; Noguchi T; Takami K; Goshima A; Miura T; Fukuda Y; Kurihara T; Okada S; Nakata K
    Osteoporos Int; 2022 Aug; 33(8):1807-1813. PubMed ID: 35362725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: Observations in a real-world setting.
    Everts-Graber J; Reichenbach S; Gahl B; Häuselmann H; Ziswiler HR; Studer U; Lehmann T
    Bone; 2022 Oct; 163():116498. PubMed ID: 35882310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial.
    Tsai JN; Lee H; David NL; Eastell R; Leder BZ
    Lancet Diabetes Endocrinol; 2019 Oct; 7(10):767-775. PubMed ID: 31447409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis.
    Palacios S; Kalouche-Khalil L; Rizzoli R; Zapalowski C; Resch H; Adachi JD; Gallagher JC; Feldman RG; Kendler DL; Wang A; Wagman RB; Adami S
    Climacteric; 2015; 18(6):805-12. PubMed ID: 26029985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors.
    Mazziotti G; Pedersini R; Vena W; Cosentini D; Carrone F; Pigni S; Simoncini EL; Torrisi R; Zambelli A; Farina D; Balzarini L; Lania AG; Berruti A
    Calcif Tissue Int; 2022 Nov; 111(5):466-474. PubMed ID: 35902384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial.
    Jamshidi A; Vojdanian M; Soroush M; Akbarian M; Aghaei M; Hajiabbasi A; Mirfeizi Z; Khabbazi A; Alishiri G; Haghighi A; Salimzadeh A; Karimzadeh H; Shirani F; Fard MRH; Nazarinia M; Soroosh S; Anjidani N; Gharibdoost F
    Arthritis Res Ther; 2022 Jun; 24(1):161. PubMed ID: 35773713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women.
    Ha J; Kim J; Jeong C; Lim Y; Kim MK; Kwon HS; Song KH; Kang MI; Baek KH
    Osteoporos Int; 2022 Jul; 33(7):1591-1599. PubMed ID: 35376989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [How to manage the rebound effect at denosumab discontinuation and avoid multiple vertebral fractures?].
    Gonzalez Rodriguez E; Lamy O; Aubry-Rozier B; Stoll D; Uebelhart B
    Rev Med Suisse; 2019 Apr; 15(647):831-835. PubMed ID: 30994986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.
    Moen MD; Keam SJ
    Drugs Aging; 2011 Jan; 28(1):63-82. PubMed ID: 21174488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.